Sold as Tandearil. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Oxyphenbutazone (sold as Tandearil), first approved Dec 21, 1960, with 0 new uses approved and 0 published complete response letters.
| Dec 21, 1960 | TandearilNDA 12542 · New molecular entity | Novartis | 18 | Discontinued |
| — | OxyphenbutazoneANDA 88399 | Watson Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA